HARBIN, China, May 6 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company has been selected by China's State Intellectual Property Office (SIPO) to participate in a unique intellectual property (IP) pilot program.
Among China's millions of public and private enterprises, approximately 800 companies from a variety of industries have been selected to join the IP pilot program. As a high growth company with a focus on technology innovation and intellectual property, Renhuang was selected as one of a handful of pharmaceutical companies from Heilongjiang province to enroll in the pilot program. As a participant of the IP pilot program, the Company will receive guidance from the SIPO in creating, using, protecting and managing intellectual property to foster innovation while protecting proprietary trademarks, technologies, processes, and products. The primary goal of the two-year IP pilot program is to help improve China's economic growth and international competitiveness by strengthening its patent and trademark system.
"The selection process for the IP pilot program was competitive and we are pleased to be a part of this unique opportunity. Our business thrives on innovation and strong intellectual property protection is a core component of our long-term success, including maintaining our leadership in the Siberian Ginseng (Acanpathax) based product market," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "Over the years, Renhuang has taken important steps to develop and manage our intellectual property portfolio. We plan to capitalize on the vast opportunities provided by this pilot program to continue to expand our intellectual property to further strengthen our competitive position."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's participation in the intellectual property pilot program, ability to build and maintain intellectual property protection around key assets, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
For more information, please contact:
Company Contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Investor Relations:
Ms. Lei Huang, Account Manager
Phone: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
